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A B S T R A C T
Background: Multiple sclerosis (MS) is characterized by a great inter-individual variability in disease course and
severity. Some patients experience a rather mild course, controversially called ‘benign MS’ (BMS). The usefulness
of this entity in clinical practice remains unclear.
Methods: We performed a literature search in PubMed, Web of Science and Cochrane Library databases from
November 1980 to December 2015, using the following key words: benign multiple sclerosis, diagnosis, imaging,
prognosis, predictive, natural history and predeﬁned inclusion criteria.
Results: Our search yielded 26 publications. Most deﬁnitions were based on the Expanded Disease Status Scale
(EDSS), which is heavily weighted towards physical disability. Between 30 and 80% of relapsing-remitting MS
patients have EDSS< 3 or 4 at 10 years after onset. Having only one relapse in the ﬁrst 5 years and EDSS≤2 at
5 years or EDSS ≤3 at 10 years appears to be predictive for a prolonged benign disease course, without
protecting against disease progression at a later stage. Evidence on the predictive value of MRI parameters
remains limited.
Conclusions: Current BMS deﬁnitions have some predictive value for future physical disability, but do not take
into account the age at EDSS and the potentially disrupting eﬀects of non-EDSS symptoms and cognitive
impairment. It appears to correspond to mild RRMS in the ﬁrst decades and its prevalence varies. Since early and
accurate prediction of BMS is not yet possible, the clinical relevance is limited. Research approaches are
suggested.
1. Introduction – background
Multiple sclerosis (MS) is a chronic inﬂammatory, demyelinating
and neurodegenerative disease with an unpredictable course and
substantial heterogeneity. Most patients start with a relapsing-remitting
(RR) course, which may be followed by a secondary progressive phase
(SPMS). A minority of subjects present with an insidious progression of
disability from onset, or primary progressive (PPMS).
MS is the most important non-traumatic cause of neurological
disability in young adults. Nevertheless, a mild course is common,
especially in the early stages. Recent cohort studies use the McDonald
diagnostic criteria and therefore include patients at an earlier stage of
disease when compared to older studies using the Poser's criteria [1].
This skews the overall outcome towards better results when considering
progression from onset or from diagnosis.
Deﬁnitions and estimates of BMS frequency vary considerably.
Whether benign MS (BMS) really exists, has even become a matter of
debate [2,3]. Because MS patients with a benign disease course are not
in need of aggressive treatments, adequate recognition is clinically
meaningful.
The aim of this review is to summarize data on BMS and evaluate its
deﬁnitions, prevalence and predictors in clinical practice.
2. Methods
English language articles and reviews from November 1980 to
December 2015 were identiﬁed through searching the PubMed, Web of
Science and the Cochrane Library databases with queries: “benign
multiple sclerosis” AND (“diagnosis” OR “imaging” OR “prognosis” OR
“predictive” OR “natural history”). Based on the reference lists, a further
search was undertaken. Using the inclusion criteria proposed by
Langer-Gould [4], we only considered articles that (1) deﬁned a BMS
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phenotype, (2) included at least 40 MS patients in total or 15 patients
per group for cross-sectional studies, (3) contained enough relevant
data to ascertain the level of possible bias and (4) reported at least
5 years of longitudinal follow-up for 80% of the studied population for
cohort studies.
The qualiﬁcation of evidence scheme for prognostic accuracy
developed by the American Academy of Neurology [5] was used to
assess the methodological quality of studies. We considered relevant
clinical questions and analysed the strength of evidence for a number of
statements, using previously published criteria [6]. Well-conducted
systematic reviews were considered to have a high level of evidence. To
avoid duplication and reduce bias, we included these results and not
those of the original studies [7]. When a predictor was studied at
several occasions in the same population, we used the most recent
publication for this predictor. The risk of bias was judged for each
statement. Two reviewers independently assessed the identiﬁed arti-
cles. Consensus was achieved in case of disagreement.
3. Results
3.1. Study selection
The PubMed/Medline search yielded 59 eligible articles. 42 were
excluded because they did not correspond to the inclusion criteria. In
the Web of Science database, we extracted another 4 articles of 40
entries. No new entries were found in the Cochrane Library. Based on
the reference lists, 23 more papers were included, resulting in 44
articles.
After correcting for double or outdated data, 29 articles were used:
10 papers on 8 population-based studies [1,8–16], 16 papers on 12
clinical cohort [17–27], 5 cross-sectional studies [28–32], 1 review [33]
and 2 systematic reviews [4,34]. Details are shown in Table 1.
3.2. Deﬁnitions
Since its ﬁrst mention in medical literature, no strong consensus has
been reached in criteria that deﬁne BMS [12]. Most deﬁnitions are
based on the Expanded Disease Status Scale (EDSS), which is non-linear
and heavily weighted towards physical disability [11]. Having EDSS or
less at a disease duration of 10, 15 or more years is used to classify those
MS patients who seem to have a less severe disease course. No
deﬁnition addressed the issue of previous or current treatment, nor
excluded patients under immunomodulating treatment. The oldest
deﬁnitions of BMS by McAlpine and Bauer included the ability to
remain active or employed after 10 or 20 years of disease as the only
criterion [35,36].
3.3. Prevalence
A systematic review on population, community and hospital-based
BMS cohorts, estimated a prevalence ranging from 6% to 64% of the
total MS population [34,37], illustrating the large variability in BMS
deﬁnitions and methodology in these studies. Part of this variation
could also be explained by geographical diﬀerences.
Table 2 summarizes prevalence data in population-based long-
itudinal cohorts. Between 30 and 80% of studied RRMS patients were
reported to have EDSS< 3 or 4 after a disease duration of 10 years or
more, as opposed to 9 to 20% in PPMS and 10 to 36.2% in mixed MS
populations. Non-population-based prevalence ranges from 0 to 70%
and is less contributory because of selection bias in clinic-based
populations (online only) [14,15,17,18,20,22–26]. Between 34 and
74% of RRMS patients have EDSS ≤3 or 4 after a disease duration of
10 years, as opposed to 0–14% of PPMS patients.
3.4. Clinical characteristics
Based on cross-sectional and clinic-based studies, patients with
EDSS-based deﬁnitions of BMS may have mental symptoms and
cognitive impairment [21,29,30,38]. While common MS symptoms
such as fatigue, anxiety and depression often impact daily functions
but do not change EDSS [12]. Cognitive diﬃculties can be considered in
speciﬁc functional systems of the EDSS (cerebral or mental), grading
possibilities are limited and subjective.
Among BMS patients, better scores for patient reported outcomes on
quality of life (QoL), fatigue and depression have been reported in
patients with lower disability (EDSS≤1.5) when compared with higher
disability (EDSS ≤3) [30,38]. Even though BMS patients have slightly
better scores for quality of life and patient reported outcomes than non-
BMS patients, they still score worse than healthy controls [28,30]. Up to
one half of BMS patients (EDSS≤3.0 after≥10 years) may suﬀer from
fatigue, depression or cognitive impairment when asked [29].
3.5. Demographic and clinical predictors of BMS
Six publications focused on predictors of BMS: 2 population-based
studies [11,12], 3 clinical cohorts [16,19,20] and 1 systematic review
[34] (Table 3).
3.5.1. Clinical phenotype at onset
A progressive disease course from onset is a strong predictor of
future disability (Table 3; not corrected for EDSS at onset). BMS usually
presents as a relapsing-remitting phenotype [11], but has occasionally
been described in PPMS [9,20]. Because PPMS is often diagnosed after
signiﬁcant irreversible disability has developed, selection bias cannot
fully be excluded. Within 20 years of disease duration, no BMS cases
(EDSS ≤3 after 10 year) with a PP course were found [8,20].
3.5.2. Relapse phenotype and frequency
There is inconclusive evidence on the predictive eﬀect of the relapse
phenotype (i.e. sensory, motor, cerebellar, etc.) at onset on having BMS
(EDSS ≤3 after 10 years) (Table 3). The Groningen study group found
that having mono-regional versus poly-regional onset symptoms is not
independently predictive for BMS in RRMS patients [20]. Having only 1
relapse in the ﬁrst 5 years after MS diagnosis increases the probability
of having BMS [34].
3.5.3. Age at onset and gender
We did not ﬁnd conclusive evidence for an eﬀect of age at onset on
the probability of having BMS (Table 3) [16,20,34], or staying benign
after a disease duration of 20 years [12]. Similarly, gender does not
appear to be an independent predictor of BMS in multivariate analyses
(Table 3), correlating with age at onset, phenotype at onset and relapse
phenotype [12,16,20,34].
3.5.4. Early disability scores and prognosis
The Olmsted County population-based cohort study with a follow-up
of 20 years showed that having an EDSS of ≤2 after 10 years was
predictive for the disease course in the following 10 years (7% chance
of developing signiﬁcant disability) [11]. In the British Colombia cohort,
about half of BMS patients (EDSS ≤3 at 10 years) did not surpass the
limit of EDSS 3 after another decade, and two thirds of BMS patients
with EDSS≤2 at 10 years were still considered benign after 20 years of
disease duration [12]. In Iceland, the proportion of BMS patients
declined from 91% at 10 years to 69% at 20 years from disease onset
in the RRMS onset group [8]. Whether the EDSS score increased due to
relapses or progression was not speciﬁed. Longitudinal data is shown in
Table 4.
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Table 1
Characteristics of articles included in this review.
N Author; year;
research group











































RRMS (100%) Not mentioned 0% 1991–2001 0% Class II















Poser 0% 1970–1981 NA Class II
























[14] Hirst; 2008; UK 379; population-based;
retrospective
Not mentioned Poser 0.3% 1985, up to 20 years
follow-up
2.4% Class III












Poser 19.4% 1985–2005 89.5% Class II




Poser Not mentioned 1983–1990 Not mentioned Class III
[21] Portaccio; 2009; Italy 63; clinical cohort; prospective BMSa (100%) Poser 30% 5 years Not mentioned Class III
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McDonald 41.7% 7–104 months 20.9% Class II




BMSc (100%) Poser 36.1% 1978–2010 34.4% Class III
[29] Amato; 2006; Italy 163; cross-sectional;
NA
BMSa (100%) Not mentioned 57% 2002–2004 NA Class III









McDonald Not mentioned 2000–2009 NA Class III
(continued on next page)
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3.6. Prognostic MRI measures in BMS
While there is a substantial amount of descriptive MRI data,
evidence on the prognostic value for BMS is scarce. Most originate
from cross-sectional studies.
In a retrospective, multicentre BMS and RRMS cohort, a high T2
brain lesion volume was associated with worsened locomotor disability
at short-term (median follow-up of 29 months) [31]. The number of T1
brain lesions in BMS patients (EDSS ≤3 after ≥15 years) was found to
predict having EDSS≤3.5 after another 5 years (hazards ratio 1.3) [21].
Two clinic-based MRI studies compared cortical lesions in a shared
cohort of 48 BMS (EDSS≤3 after≥15 years, 50% treated) to 96 early
RRMS patients (EDSS ≤3 at ≥5 years, 95% treated) [27,32]. A low
number of intra-cortical lesions, cortical lesion volume at baseline,
cortical lesion volume change over 6 years and higher cortical thickness
of selected gyri appeared to be independent predictors of BMS (cross-
validated) [27].
While we found many studies on MRI spectroscopy, magnetization
transfer ratio histogram analysis and atrophy rate in MS and their
correlation with disease activity, disability and cognition, none of these
studies were aimed at predicting BMS.
4. Discussion
BMS is a challenging concept. Based on our systematic review of 29
articles, using stringent criteria, a substantial proportion of untreated
patients with RRMS appear to have a mild disease course over the ﬁrst
10 to 20 years of the disease. Most study groups use EDSS 3 or lower at
a disease duration of 10, 15 or more years to classify those MS patients
who seem to have BMS. While not protecting against disease progres-
sion at a later stage, current EDSS-based BMS deﬁnitions have some
predictive value for future disability.
However, the EDSS scale is skewed towards ambulation and under-
















[32] Calabrese; 2009; Italy 144; cross-sectional; NA BMSa (33.3%),
early RRMS
(66.7%)






























Not mentioned 1950–1997 NA Class II
BMS: benign multiple sclerosis, deﬁned as MS with a EDSS ≤3 and a disease duration of ≥15 years (b ≥ 10 years, c ≥ 20 years), or d DSS≤ 3 (e ≤ 2)≥ 10 years from onset.
CIS: clinically isolated syndrome.
DMT: disease modifying treatment.
EDSS: expanded disease status scale.
NA: not applicable.
PPMS: primary progressive multiple sclerosis.
PRMS: progressive relapsing multiple sclerosis.
RRMS: relapsing-remitting multiple sclerosis.
SPMS: secondary progressive multiple sclerosis.
Table 2
Chronological view of BMS prevalence estimations, based on EDSS deﬁnitions in population-based cohorts.
Study group Time frame for inclusion
(follow-up)




(up to 50 years)
372 RRMS/SPMS (n = 280), PPMS/PRMS (n = 92) (Poser) EDSS< 4 at 15 years 80% relapsing onset
20% progressive onset
Scotland [10] 1970, 1981, 1987
(up to 60 years)
1055 Relapsing onset (n = 960) Progressive onset (n = 95) EDSS< 3 at 10 years 26%
5%
British Colombia [9] 1980–2003
(up to 23 years)
552 PPMS (Poser) EDSS ≤3 at 10 years 9%
UK [14] 1985
(up to 20 years)
379 Deﬁnite of probable MS (Poser) EDSS ≤4 at 10 years 22.1%
Olmsted County [11] 1991–2001
(up to 20 years)
162 RRMS EDSS ≤4 at 10 years 30.25%
Hordaland County [16] 1976–1986
(up to 27 years)
230 RRMS (n = 185)
PPMS (n = 45)
(McDonald)
EDSS ≤3 at 10 years 1995: 37.6%
2003: 24.2%
BMS: benign multiple sclerosis.
EDSS: expanded disease status scale.
RRMS: relapsing-remitting multiple sclerosis.
SPMS: secondary progressive multiple sclerosis.
PPMS: primary progressive multiple sclerosis.
PRMS: progressive relapsing multiple sclerosis.
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cognitive impairment. Assessment of these symptoms is not routinely
integrated in clinical practice, even though they have been associated
with immune-related processes [39] and brain atrophy [38], respec-
tively. The fact that disease activity in MS may be hidden, adds to the
controversy surrounding BMS. The same holds true for current deﬁni-
tions of the “no evidence of disease activity” status, as more than half of
the treated RRMS patients who receive this status showed cognitive
worsening [40].
While not all population-based studies included BMS as a separate
entity and some BMS patients may not seek medical attention, the
Table 3
Demographic and clinical predictors in BMS (EDSS ≤3 after 10 years).
Variable Statement Rating of studies Evidence classiﬁcation
Disease phenotype at onset A relapsing phenotype at onset increases the probability of
having BMS by roughly threefold [20].
Conﬁrmed: 2 high quality [20,12], 1
low quality [16]
Strong evidence that a relapsing phenotype
at onset increases the probability of having
BMS
Age at onset in RRMS Younger onset age increases the probability of having
BMS, when compared to an older age at onset.
Conﬁrmed: 1 systematic review [34], 1
low quality [16]
Not conﬁrmed in multivariate analysis
of 1 high quality [20]
Inconclusive evidence
Gender in RRMS Female gender increases the probability of having BMS,
when compared to male gender.
Not conﬁrmed: 1 systematic review
[34], 2 high quality [20,12], 1 low
quality [16]
Strong evidence that gender has no
predictive eﬀect for BMS in RRMS patients
Relapse phenotype at onset
in RRMS
Onset with aﬀerent symptoms increases the probability of
having BMS, while onset with eﬀerent symptoms
decreases this probability in RRMS.
Both conﬁrmed: 1 systematic review
[34]
Motor symptoms conﬁrmed: 1 high
quality [11]
Both not conﬁrmed: 2 high quality
[20,12], 1 low quality [16]
Aﬀerent not conﬁrmed: 1 low quality
[19]
Inconclusive evidence
Early relapse rate Having only 1 relapse in the ﬁrst 5 years increases the
probability of having BMS.
Conﬁrmed: 1 systematic review [34], 1
high quality [20]
Strong evidence
EDSS at 5–10 years from
onset in RRMS
EDSS≤2 at 5 years or EDSS≤3 at 10 years increases the
probability of still having EDSS ≤3–4 after another
10 years.
Conﬁrmed: 3 high quality [11,20,12] Strong evidence
Bold and underlined words signiﬁes aesthetics.
BMS: benign multiple sclerosis.
RRMS: relapsing-remitting multiple sclerosis.
PPMS: primary progressive multiple sclerosis.
EDSS: expanded disease status scale.
Table 4
Proportion of BMS patients that stay benign at diﬀerent follow-up intervals.
Population
(number of BMS at start of follow-up)
18 years since MS diagnosis
(BMS/still in follow-up)
20 years since MS diagnosis
(BMS/still in follow-up)
30 years since MS diagnosis
(BMS/still in follow-up)
50 years since MS diagnosis
(BMS/still in follow-up)
Iceland [8]a
Relapsing onset (n = 218) 81% (86/165) 69% (56/81)
Progressive onset (n = 72) 16% (9/58) 0% (0/27)
Olmsted County [11]b
RRMS (n = 49) 72.3% (34/47)
British Colombia [12] Ɨ
BMSa (n = 200), of which:
Relapsing onset (n = 196)




BMSa (n = 151), of which:
Relapsing onset (n = 142)
Progressive onset (n = 9)
69% (35/51) 22.9% (8/35)
(all relapsing onset)
Norway [16] ƗƗƗ
BMSa (n = 86) 65.1% (56/86)
Italy [21] ƗƗƗƗ
BMSc,d (n = 63) 68.3% (43/63)
Gothenborg
RRMS (n = 202) [13]a 5.4% (11/202)
PPMS (n = 44) [1]a 0% (0/44)
BMS: benign multiple sclerosis, deﬁned by a (EDSS ≤3) or b (EDSS ≤4) at ≥10 years disease duration, or c (EDSS ≤3) or d (EDSS ≤3.5) at ≥15 years disease duration.
RRMS: relapsing-remitting multiple sclerosis.
PPMS: primary progressive multiple sclerosis.
Ɨ 23% treated by an immunomodulatory drug (43/46 after diagnosis of BMS). Results for the untreated population were “in the same direction as for the main analysis”. Data not speciﬁed.
ƗƗ 14.5% was ever treated by Interferon bèta. Data not speciﬁed.
ƗƗƗ Unclear whether participants are treatment naïve.
ƗƗƗƗ 31.7% treated by an immunomodulatory drug at start of follow-up, 32.6% of those that stayed BMS.
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estimated prevalence ranges from 30 to 80% when considering RRMS
patients who have EDSS< 3 or 4 at 10 years or more after onset. About
half on them maintains this status up to 20 years, suggesting up to one
third of MS patients maintains EDSS< 4 over several decades
[8–11,15,16]. Recent prevalence data on BMS are lacking. However,
based on the progressively lengthening time from diagnosis to EDSS 6
[33], the recognition of milder cases using the new McDonald criteria
and changing temporal trends, there is no evidence to suggest that the
incidence of BMS may be decreasing.
The treatment era has changed our view on MS. The variable length
of the interval to (E)DSS 3 in RRMS, as shown in Leray's Figure 1 [41],
is often presented as the therapeutic window to delay the onset of
secondary progression and to motivate early and aggressive treatment.
After having reached the ﬁrst disability milestone, the second phase of
DSS progression appears to run in parallel over the whole population,
and demographics and initial disease characteristics no longer seem to
aﬀect disability progression [41]. A longlasting ﬁrst phase (up to
several decades) may correspond to BMS. Similar to RRMS being
followed by SPMS, this does not entirely protect against future
disability progression.
Ideally, predictors should enable us to distinguish those patients
who may be in need of early and aggressive treatment from those who
are not. This is not the case for BMS. Nevertheless, having a relapsing-
remitting onset, only one relapse in the ﬁrst ﬁve years and an EDSS of 2
or less at 5 years or EDSS of 3 or less at 10 years of disease duration are
strong predictors for having BMS and remaining BMS for another
10 years. The age at onset appears not to be an independent predictor,
which could be explained by recall bias, the diﬃculties in assessing the
true onset of disease, methodological issues and the relatively low
number of included studies. Similarly, there is no evidence for gender to
independently predict BMS [12,16,20,34] in multivariate analysis
[16,20]. In view of the strong eﬀect of age at onset and gender on
the clinical phenotype and probability of disease progression [42], we
assume that both age at onset and gender are interacting with the
clinical disease phenotype [1]. While a younger age at onset is often
reported as indicative of a better prognosis, these patients reach
ambulatory landmarks at a younger age when compared to patients
older at onset [43].
We found only limited data on early MRI predictors, probably
because of our stringent inclusion criteria. Most MRI studies on BMS
were either cross-sectional, had a short duration or small sample sizes.
Prognostic properties of advanced and quantiﬁed MRI measures are
promising, but currently insuﬃcient on an individual level.
Our review has the strength of focusing on BMS, using predeﬁned
criteria for inclusion and quality assessments [4–6]. However, a direct
comparison between published studies and cohorts was not possible.
We were not able to control for systematic methodological diﬀerences
between studies. Also, the low number of natural history studies and
population-based cohorts with a deﬁned BMS subpopulation may have
limited the validity of our ﬁndings. Furthermore, most studies contain a
certain degree of treated MS patients, making it diﬃcult to attribute
conclusions to a benign disease course or treatment response. Solely
selecting untreated MS patients could result in small population sizes
and possibly a selection bias, as not all BMS patients seek medical
attention. Finally, the potential contribution of lifestyle and environ-
mental factors has not been taken into account in these studies. There is
increasing evidence that these factors contribute to the risk and course
of MS [44].
As neurological disability appears to evolve more slowly than
estimated from older natural history cohorts [33,45,46], further pro-
spective, long-term studies are needed to ﬁnd valid predictors of the
long-term disease course in MS. In addition to demographics, clinical
and MRI characteristics, we propose to include neuropsychological
assessments and to investigate the contributory role of lifestyle and
environmental factors. Considering the age at early disability mile-
stones may provide more useful information than the time from disease
onset to these milestones. The recently developed age-related MS
Severity Score may be a good start to measure the relative severity of
disability [39]. The ideal study population may consist of patients with
a clinically isolated syndrome (CIS), which are not necessarily treated
from the start. Finding predictors of BMS in those patients who
eventually develop multiple sclerosis may be the mission [47]. Search-
ing for predictors that delay the onset of secondary progression in
treated and untreated RRMS patients may be an even greater challenge.
5. Conclusion
Benign multiple sclerosis appears to correspond to mild RRMS in the
ﬁrst decades and is part of the whole spectrum of MS. In view of the
potential burden of less visible symptoms, the limited predictability and
uncertain contribution of age-related and lifestyle factors, further
prospective studies are needed to increase our understanding of this
entity. This area of research is challenging as recent temporal trends
suggest a more slowly evolving neurological disability over time. We
propose to extend BMS prediction studies to CIS patients in order to ﬁnd
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